SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-18-135128
Filing Date
2018-04-26
Accepted
2018-04-26 17:09:03
Documents
8
Period of Report
2018-04-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d578291d8k.htm 8-K 19855
2 EX-1.1 d578291dex11.htm EX-1.1 152093
3 EX-5.1 d578291dex51.htm EX-5.1 7188
4 EX-99.1 d578291dex991.htm EX-99.1 8520
5 EX-99.2 d578291dex992.htm EX-99.2 9166
6 GRAPHIC g578291g0426234646400.jpg GRAPHIC 2525
7 GRAPHIC g578291g0427003458209.jpg GRAPHIC 4933
8 GRAPHIC g578291g0427003821714.jpg GRAPHIC 4840
  Complete submission text file 0001193125-18-135128.txt   215695
Mailing Address 950 WINTER STREET WALTHAM MA 02451
Business Address 950 WINTER STREET WALTHAM MA 02451 (858) 909-0749
Eloxx Pharmaceuticals, Inc. (Filer) CIK: 0001035354 (see all company filings)

IRS No.: 841368850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-31326 | Film No.: 18779605
SIC: 8731 Services-Commercial Physical & Biological Research
Office of Trade & Services